Quince Therapeutics Inc

Quince Therapeutics’ CEO exercise of a 1‑million‑share option signals long‑term confidence in its bone‑disease pipeline and could spark a valuation reset.

Quince Therapeutics insider options: 200k shares, zero price, 48‑month vesting tied to bone‑targeted therapy milestones—dilution risks, market volatility, and investor confidence explained.